UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 144,623 Shares of LifeStance Health Group, Inc. $LFST

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in LifeStance Health Group, Inc. (NASDAQ:LFST) by 2.4% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 5,947,600 shares of the company’s stock after selling 144,623 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in LifeStance Health Group were worth $63,699,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of LFST. Larson Financial Group LLC lifted its position in LifeStance Health Group by 19,952.6% during the 4th quarter. Larson Financial Group LLC now owns 3,810 shares of the company’s stock worth $27,000 after acquiring an additional 3,791 shares during the last quarter. KBC Group NV acquired a new stake in shares of LifeStance Health Group in the first quarter valued at about $29,000. EverSource Wealth Advisors LLC grew its position in shares of LifeStance Health Group by 359.1% in the first quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company’s stock valued at $44,000 after purchasing an additional 5,404 shares during the last quarter. Bayesian Capital Management LP bought a new position in shares of LifeStance Health Group in the second quarter worth about $52,000. Finally, PNC Financial Services Group Inc. increased its stake in shares of LifeStance Health Group by 615.3% in the first quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company’s stock worth $59,000 after purchasing an additional 7,987 shares during the period. Institutional investors own 85.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on LFST. KeyCorp increased their target price on LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Weiss Ratings raised LifeStance Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Barclays upped their price target on LifeStance Health Group from $9.00 to $13.00 and gave the stock an “overweight” rating in a report on Tuesday, July 14th. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, BTIG Research raised their price objective on shares of LifeStance Health Group from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $12.38.

Insider Transactions at LifeStance Health Group

In related news, Director Robert Bessler sold 894,337 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the transaction, the director directly owned 539,763 shares in the company, valued at approximately $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Lisa K. Miller sold 47,912 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $10.85, for a total value of $519,845.20. Following the completion of the transaction, the chief operating officer directly owned 281,289 shares of the company’s stock, valued at approximately $3,051,985.65. This trade represents a 14.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 14,629,850 shares of company stock worth $154,952,012 over the last 90 days. Insiders own 3.50% of the company’s stock.

LifeStance Health Group Stock Up 2.3%

NASDAQ LFST opened at $12.89 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.38 and a current ratio of 1.38. The firm has a 50-day simple moving average of $11.38 and a 200 day simple moving average of $8.73. LifeStance Health Group, Inc. has a twelve month low of $4.77 and a twelve month high of $13.15. The stock has a market cap of $5.00 billion, a PE ratio of 99.16 and a beta of 1.22.

LifeStance Health Group (NASDAQ:LFST) last released its earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The business had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. During the same period last year, the business earned ($0.01) earnings per share. The firm’s revenue for the quarter was up 26.1% compared to the same quarter last year. On average, research analysts forecast that LifeStance Health Group, Inc. will post 0.16 EPS for the current year.

LifeStance Health Group Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.